FDA Documents Signal Favorable Review for Grail Galleri Multi-Cancer Blood Test

The documents highlight Galleri's reported sensitivity of 76.3 percent for stage I-III cancers across 12 types in the PATHFINDER 2 study, with specificity above 99 percent. This builds on the earlier CCGA observational cohort of 15,000 participants where positive predictive value reached 44 percent. FDA advisory committee review scheduled for September 23 will weigh these metrics against risks of false positives triggering unnecessary procedures.

Reimbursement hinges on full approval rather than the current laboratory-developed test status. Medicare coverage could expand access beyond the 100,000 patients tested to date, yet the agency notes the absence of randomized outcome data showing mortality reduction. Observational designs leave open questions on lead-time bias and overdiagnosis.

Prior liquid-biopsy setbacks, including the 2022 Guardant Shield rejection, underscore that surrogate endpoints like stage shift do not automatically translate to clinical benefit. Grail's Illumina spin-off structure adds regulatory scrutiny on post-market surveillance commitments.

Next steps require the committee vote and subsequent FDA decision by early 2027, with any approval likely conditioned on a confirmatory randomized trial measuring cancer-specific mortality.